An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.
The results of ENGAGE AF-TIMI 48 demonstrate that edoxaban 60 mg once daily is noninferior to well-managed warfarin in the prevention of stroke and SEEs in patients with NVAF. In addition, the trial results demonstrate that edoxaban 60 mg once daily led to statistically significantly fewer major bleeding events than did warfarin. Overall, the trial was well conducted, and the primary results can be considered reliable.
Indirect evidence supports the results of the efficacy and safety of edoxaban compared with warfarin. The IDC of edoxaban with other DOACs cannot reliably estimate relative efficacy or safety from the currently available evidence network. A direct comparison between different DOACs is needed to establish the comparative efficacy and safety of these drugs.
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Your browsing activity is empty.
Activity recording is turned off.
See more...
